Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

• Main Authors: Byrski, T, Dent, R, Blecharz, P, Foszczynska-Kloda, M, Gronwald, J, Huzarski, T, Cybulski, C, Marczyk, E, Chrzan, R, Eisen, A, Lubinski, J, Narod, S.A
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: aromatase inhibitor; BRCA1 protein; cisplatin; cyclophosphamide; dexamethasone; docetaxel; doxorubicin; epidermal growth factor receptor 2; estrogen receptor; fluorouracil; ondansetron; pabi dexamethason; progesterone receptor; unclassified drug; antineoplastic agent; adult; aged; anemia; article; breast cancer; cancer chemotherapy; cancer survival; clinical article; drug withdrawal; female; gene mutation; heterozygote; human; metastasis; multiple cycle treatment; nausea; neutropenia; open study; overall survival; phase 2 clinical trial; treatment outcome; Breast Neoplasms; clinical trial; computer assisted tomography; genetics; metabolism; middle aged; mortality; multicenter study; mutation; pathology; tumor suppressor gene; Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Genes, BRCA1; Heterozygote; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Tomography, X-Ray Computed; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183230
• Institution: National University of Singapore

10.1186/bcr3231